Alzheimer's News Today Home | Alzheimer's News Today
The Web's Daily Resource for Alzheimer's News| Alzheimer's News Today
The Web's Daily Resource for Alzheimer's News| Alzheimer's News Today
Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.| Alzheimer's News Today
Otsuka is stopping the development of AVP-786, its experimental therapy to treat agitation in people with Alzheimer’s disease.| Alzheimer's News Today
Alzamend Neuro is partnering with Mass General Hospital for a Phase 2 trial of AL001, a next-generation lithium drug for Alzheimer’s dementia.| Alzheimer's News Today
Fujirebio asked the FDA to approve its blood test for Alzheimer's disease, which would be the first commercially available test of its kind.| Alzheimer's News Today
BioXcel plans to test BXCL501 for treating agitation in Alzheimer’s disease dementia in patients in nursing and assisted living facilities.| Alzheimer's News Today
As columnist Ray Burow watched her mother's dementia progress, she often returned to a friend's wise words about coping with loss.| Alzheimer's News Today
Wallowing in self-pity is tempting in the wake of an Alzheimer's diagnosis, but it's crucial to keep moving forward, says columnist Ray Burow.| Alzheimer's News Today
A reader's comment prompts columnist Ray Burow to reinforce the purpose of her column: providing hope to those with an Alzheimer's diagnosis.| Alzheimer's News Today
A breast cancer diagnosis is particularly problematic — yet possible — for women caregivers, columnist Ray Burow writes.| Alzheimer's News Today
Columnist Ray Burow remembers her recently passed mother-in-law, who remained loving and loved during her short-term memory loss.| Alzheimer's News Today
Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
The full approval of Eisai and Biogen’s Leqembi clears the way for broader Medicare coverage of the treatment, which has been limited.| Alzheimer's News Today
Biogen is discontinuing development and commercialization of its controversial Alzheimer's treatment Aduhelm to focus its efforts on Leqembi.| Alzheimer's News Today
One-year data from a Phase 2 trial's extension showed safe and rapid, sustained drops in beta-amyloid levels in early stage patients.| Alzheimer's News Today
Simufilam, a small molecule targeting the filamin A protein, is being tested in clinical trials to potentially treat Alzheimer's disease.| Alzheimer's News Today
Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.| Alzheimer's News Today
Columnist Ray Burow now understands that those who get an Alzheimer's diagnosis need time to come to grips with the disease.| Alzheimer's News Today
The Alzheimer's Association is urging patients, caregivers, and advocates to "take action now" and support legislation this awareness month.| Alzheimer's News Today
The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S. policies.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second quarter of this year after the experimental treatment failed to meet key Phase 3 trial goals for improving cognition and daily function. In REFOCUS-ALZ (NCT05026177), patients treated with simufilam showed no significant improvements in cognitive functioning, as […] The post Simufilam fails to meet Phase 3 trial goals; development discontinued appeared first on Alzheime...| Alzheimer's News Today – The Web's Daily Resource for Alzheimer's News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Alzheimer's News Today
Early menopause and poor brain-connection health may interact to increase Alzheimer's disease risk in women, a study found.| Alzheimer's News Today
The U.S. FDA has approved monthly maintenance dosing for Leqembi, a treatment for early Alzheimer’s disease.| Alzheimer's News Today
Winter in a cold climate can add challenges when caregiving for someone with dementia, columnist Ray Burow writes.| Alzheimer's News Today
The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ADVANCE-2 didn't.| Alzheimer's News Today
Columnist Ray Burow, grieving the loss of her dear friend Richard Allen Farmer, reflects on how he cared for her mother, who had Alzheimer's.| Alzheimer's News Today
Learn more about the alzheimer's disease treatment options that may help reduce the symptoms or slow progression of Alzheimer's.| Alzheimer's News Today
Experts in Alzheimer’s and dementia care explain the challenges of getting an early and accurate diagnosis and what can be done to solve it.| Alzheimer's News Today
Early-onset Alzheimer's is a rare form of dementia that occurs between ages 30 and 60, and may affect several members of a single family.| Alzheimer's News Today
Columnist Ray Burow offers factors to consider when discussing whether nursing home care or at-home care is better for your loved one.| Alzheimer's News Today
A rare APOE gene mutation may protect against Alzheimer's by stopping the spread of toxic tau protein clumps in the brain, a study found.| Alzheimer's News Today
Patricia Inacio is a science writer for Alzheimer's News Today with a PhD in cell biology. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Buntanetap lowered amyloid-beta and tau levels in people with early Alzheimer's disease and its developer Annovis Bio is planning more trials.| Alzheimer's News Today
Lindsey Shapiro is a science writer for Alzheimer's News Today with a PhD in neuroscience. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Steve Bryson is a science writer for Alzheimer's News Today with a PhD in biochemistry. He covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Exelon (rivastigmine) is a drug treatment to manage the symptoms of Alzheimer’s disease (AD), produced by Novartis.| Alzheimer's News Today
Aricept (donepezil) is an approved oral medication that treats the symptoms of dementia caused by Alzheimer’s disease by improving cognition and function.| Alzheimer's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
CT1812 is an oral medication being developed by Cognition Therapeutics, now in clinical testing, to possibly treat mild-to-moderate Alzheimer’s disease by preventing the build up of beta-amyloid in the brain.| Alzheimer's News Today
Amylyx Pharmaceuticals' oral therapy candidate AMX0035 improves levels of several biomarkers associated with Alzheimer's, per a new analysis.| Alzheimer's News Today
Under-the-skin injections worked better in trial than the approved Leqembi formulation in clearing harmful amyloid plaques in Alzheimer's.| Alzheimer's News Today
Just-released full data from the Phase 3 Clarity AD trial show lecanemab can significantly slow dementia in early-onset Alzheimer’s patients.| Alzheimer's News Today
Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.| Alzheimer's News Today
Anavex 2-73 is an oral therapy, now in clinical testing, that activates the sigma-1 receptor to potentially modify the course of Alzheimer’s disease.| Alzheimer's News Today
Alpha Cognition’s ALPHA-1062 for Alzheimer’s showed efficacy in a trial as a bioequivalent substitute for the approved therapy Razadyne.| Alzheimer's News Today
Alpha Cognition’s oral tablet ALPHA-1062 may be a bioequivalent to galantamine hydrobromide – sold as Razadyne – for Alzheimer’s disease.| Alzheimer's News Today
Razadyne (Galantamine) is a treatment to slow the progression of symptoms in mild to moderate Alzheimer’s disease (AD), produced by Janssen.| Alzheimer's News Today
Alzheimer's disease destroys brain cells, affecting a person's behavior, memory, speech, thinking. Here's suggestions on living with Alzheimer's Disease.| Alzheimer's News Today
The immunotherapy Leqembi, formerly BAN2401, is now FDA-approved for slowing cognitive decline in patients with Alzheimer's disease.| Alzheimer's News Today
Read a summary of the causes Alzheimer's disease, inclouding neurofibrillary tangles, inflammation, vascular and environmental factors, genetics and aging.| Alzheimer's News Today
Being a sole caregiver for a loved one with Alzheimer's is hard work, says columnist Ray Burow, but help and resources are available.| Alzheimer's News Today
Marisa Wexler is a senior science writer for Alzheimer's News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Donanemab slowed cognitive, functional ability declines in early Alzheimer’s disease, according to top-line data from a Phase 3 trial.| Alzheimer's News Today
Kisunla (donanemab-azbt) is an antibody-based therapy approved in the U.S. for adults with early symptomatic Alzheimer’s disease.| Alzheimer's News Today
Columnist Ray Burow explains how her mother's Alzheimer's called to mind Dickens' quote about the "spring of hope" and "winter of despair."| Alzheimer's News Today
Diagnosis of Alzheimer's disease involves assessing patients' medical history, symptoms, lab tests, and using brain imaging to rule out other conditions.| Alzheimer's News Today
Learn more about the symptoms of Alzheimer’s disease, the most common form of dementia, and its several stages. Alzheimer's symptoms may be different for each patient.| Alzheimer's News Today
Taking on caregiving for a loved one with Alzheimer's can seem impossible, says columnist Ray Burow, but only until it's done.| Alzheimer's News Today
There is great value in the relationship between grandparents and grandchildren, columnist Ray Burow says, even if Alzheimer's is involved.| Alzheimer's News Today
Margarida Maia is a science writer for Alzheimer's News Today with a PhD in biomedical sciences. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
No description.| Alzheimer's News Today
Treatment with Lomecel-B in early Alzheimer's patients led to improvements in cognitive tests relative to a placebo in a clinical trial.| Alzheimer's News Today
After her father passed away, columnist Ray Burow had to help her mother, who had Alzheimer's, process her emotions and grief.| Alzheimer's News Today
Category archive page for Columns.| Alzheimer's News Today
Experimental blarcamesine (Anavex 2-73) was able to slow cognitive and functional decline in early Alzheimer’s patients over a year, data show.| Alzheimer's News Today
Zunveyl, a new oral mild-to-moderate Alzheimer's therapy, showed bioequivalence to galanotamine but fewer GI issues like nausea in studies.| Alzheimer's News Today
Columnist Ray Burow, reflecting on caregiving for her late mother, ponders if it's sometimes OK to lie to a person with Alzheimer's disease.| Alzheimer's News Today
The use of Montelukast oral film was shown to improve cognition in patients with mild to moderate Alzheimer's in a Phase 2 clinical trial.| Alzheimer's News Today
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild Alzheimer’s disease.| Alzheimer's News Today
Foralumab is an antibody being developed by Tiziana Life Sciences that's designed to block CD3, a protein on the surface of immune T-cells.| Alzheimer's News Today
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
The safety and efficacy of buntanetap therapy are comparable in early Alzheimer’s patients regardless of APOE4 status, per new trial data.| Alzheimer's News Today
With the high temperatures expected this summer, columnist Ray Burow recalls tips she used to help loved ones with dementia handle the heat.| Alzheimer's News Today
The Phase 2 study will further assess SNK01's safety and its efficacy in about 30 patients who'll receive it every three weeks up to a year.| Alzheimer's News Today
A decision from the FDA on once-monthly maintenance dosing of Leqembi in early Alzheimer's is expected by Jan. 25, 2025.| Alzheimer's News Today
An advisory committee to the U.S. Food and Drug Administration (FDA) unanimously voted in favor of donanemab for early Alzheimer's.| Alzheimer's News Today
Columnist Ray Burow can attest to the challenges that sandwich generation caregivers face, but says her children learned valuable lessons.| Alzheimer's News Today
Buntanetap, a small molecule from Annovis Bio, improved cognitive function in people with mild Alzheimer’s with certain biomarkers.| Alzheimer's News Today
Eisai has started a rolling application seeking U.S. FDA approval of an under-the-skin injection version of Leqembi for early Alzheimer’s.| Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease.| Alzheimer's News Today
A total of 1,929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today
